Strain specific Ces1c expression analysis in homozygous B-Ces1c KO mice(CB-17 SCID) by Western blot. Liver and serum were collected from CB17-SCID mice (+/+) and homozygous B-Ces1c KO mice(CB-17 SCID) (-/-), and then analyzed by western blot with species-specific anti-Ces1c antibody. 40 μg total proteins were loaded for western blotting analysis. Ces1c was not detected in liver and serum of homozygous B-Ces1c KO mice(CB-17 SCID) (-/-).

In vitro analysis of the kinetics of Ab1-vcMMAE (in-house) in B-Ces1c KO mice(CB-17 SCID) . Ab1-vcMMAE (in-house) was added to CB-17 SCID mice, B-Ces1c KO mice(CB-17 SCID), human plasma, and 0.5% BSA at a concentration of 100 µg/mL and incubated at 37 ℃ for 0h, 1d, 3d, 7d, and 14d. The free MMAE content was assessed at each time point. At 14 days, the release rate of free MMAE in CB-17 SCID mice was approximately 8%, while the release rates in B-Ces1c KO mice(CB-17 SCID) were similar to those in human plasma and 0.5% BSA. This indicates that B-Ces1c KO mice(CB-17 SCID) provide a good pharmacokinetic/pharmacodynamic model for ADC drugs that are susceptible to cleavage by Ces1c.